-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer is the most common cancer among men in the United States and the second leading cause of cancer deaths.
Manage FDA 18 18 F fluciclovine 18 18 F fluciclovine 99m 99m Tc
Prostate-specific membrane antigen (PSMA) is overexpressed on prostate cancer cells, and radiotracers targeting this antigen are increasingly used to assess the degree of disease in prostate cancer patients.
68 68 Ga 68 68 Ga 68 68 Ga 18 18 F fluciclovine 68 68 Ga
There are obvious differences in the health of prostate cancer patients of different races/ethnicities.
diagnosis
In order to identify potential differences in access to the latest health services in the intermediate steps of providing health services, such differences may lead to differences in prostate cancer health outcomes.
Matthew D.
This study reviews all 18 F - fluciclovineand 68 Ga- PSMA-11 PET studies conducted at the University of California, San Francisco from October 2015 to January 2020 .
18 18 F fluciclovine68 68 Ga
The study included 1,756 patients, of which 1,502 patients received 68 Ga -PSMA-11 treatment, and 254 patients received 18 F - fluciclovine .
68 68 Ga 18 18 F fluciclovine
Patients receiving 18 F - fluciclovine (average 69.
18 18 F fluciclovine 68 18 18 F fluciclovine 68
The probability of black patients receiving 18 F - fluciclovine imaging is approximately 4 times that of 68 Ga -PSMA-11 (OR, 3.
Black patients receiving black patients receiving 18 is 18 is 18 is F.
Although Although 18 is 18 is 18 is F.
snmjournals.
snmjournals.
Leave a message here
